Komajda M, McMurray JJ, Beck-Nielsen H, Gomis R, Hanefeld M, Pocock SJ, Curtis PS, Jones NP, Home PD
Benefitfocus knows every organization is unique, but with insights around GLP-1 usage by demographic and tips to mitigate costs and risks, organizations can set the foundation
Tirzepatide: dual GIP/GLP-1 receptor agonism Tirzepatide demonstrated that dual incretin receptor agonism could produce greater weight loss than earlier single-receptor approaches
Significance and regulation of lipid metabolism
Schiller LR, Santa Ana CA, Porter J, Fordtran JS
Studies found that HDL in the plasma of CVD patients with high TMAO levels was significantly reduced, resulting in inhibition of the RCT pathway and cholesterol accumulation in macrophages (64)